53BP1 expression as a biomarker to differentiate thyroid follicular tumors

• Material Type: 博士論文
• Title: 53BP1 expression as a biomarker to differentiate thyroid follicular tumors
• Author/Editor: 佐藤, 綾子
• Author Heading: 佐藤, 綾子
• Publication, Distribution, etc.: Bioscientifica Ltd
• Publication Date: 2022-03-02
• Publication Date (W3CDTF): 2022-03-02
• Alternative Title: 甲状腺濾胞性腫瘍における53BP1を用いた術前鑑別の有用性
• Periodical title: Endocrine Connections
• No. or year of volume/issue: 10 3
• Volume: 10
• Issue: 3
• Pages: 309-315
• ISSN (Periodical Title): ISSN : 2049-3614
• Degree grantor/type: Nagasaki University (長崎大学)
• Date Granted: 2022-03-02
• Dissertation Number: 甲医歯薬第1405号
• Degree Type: 博士(医学)
• Text Language Code: eng
• Subject Heading: 53BP1; genomic instability; immunofluorescence; thyroid follicular tumor; liquid-based cytology
• Target Audience: 一般
• Note (General): We have previously reported that the expression of p53-binding protein 1 (53BP1) in nuclear foci (NF), a marker reflecting DNA damage response (DDR), detected using immunofluorescence (IF) is useful to estimate the malignant potency of diverse cancers. In this prospective study, we clarified the impact of 53BP1 expression via IF as a biomarker to differentiate thyroid follicular tumors (FTs) with liquid-based cytology (LBC). A total of 183 consecutively obtained-LBC samples, which were preoperatively suspected as FTs, were analyzed. Before histological diagnosis, the type of 53BP1 immunoreactivity in LBC was classified as follows: low DDR type, one or two NF; high DDR type, three or more NF; large foci type, larger than 1.0 μm; abnormal type, intense nuclear staining. Among the 183 cases, 136 cases were postoperatively diagnosed as FTs, including adenomatous goiter (AG, n = 30), follicular adenoma (FA, n = 60), FT-uncertain malignant potency (FT-UMP, n = 18), and follicular carcinoma (FC, n = 28), and 47 cases were diagnosed as tumors other than FTs or technically inadequate materials. Total 136 FT cases were collated with the type of 53BP1 immunoreactivity in LBC. The mean incidence expressing abnormal 53BP1 expression was significantly higher in FC than FA (9.5% vs 2.6%, P-value < 0.001). When adopting 4.3% as a cut-off value to distinguish FC from FA, the sensitivity, specificity, positive predictive value, and negative predictive value were 89.3, 83.3, 71.4, and 94.3%, respectively. Therefore, IF analysis of 53BP1 expression can be employed as a novel technique to diagnose FTs and to distinguish between different types of FTs using LBC.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第1405号 学位授与年月日:令和4年3月2日; Author: Ayako Sato, Katsuya Matsuda, Takahiro Motoyama, Zhanna Mussazhanova, Ryota Otsubo, Hisayoshi Kondo, Yuko Akazawa, Miyoko Higuchi, Ayana Suzuki, Mitsuyoshi Hirokawa, Akira Miyauchi, Takeshi Nagayasu, and Masahiro Nakashima; Citation: Endocrine Connections, 10(3), pp. 309–315; 2021; identifier:Nagasaki University (長崎大学), 博士(医学) (2022-03-02)
• Source: fulltext; https://nagasaki-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=27365&item_no=1&attribute_id=70&file_no=1
• Access Restrictions: インターネット公開
• Rights (production): © 2021 The authors. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
• Related Material: http://hdl.handle.net/10069/00041408
• Related Material (DOI): 10.1530/EC-20-0630
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 長崎大学 : 長崎大学学術研究成果リポジトリ